VivoSeq
Oncology

Oral Cancer

0

Pipeline Programs

4

Active Trials

0

Companies Involved

Oral Cancer is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

10

clinical trials

Completed6 · 60%
Recruiting4 · 40%

Trial Activity

10 trials

Erlotinib Prevention of Oral Cancer (EPOC)
Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00402779·303 enrolled
Addition of Aspirin to Standard of Care in Oral Cancer
Completed··Phase 2/3·NCT05865548·60 enrolled
Using MASL to Combat Oral Cancer
Completed·RRowan University·Phase 1·NCT04188665·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)